{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:18:18Z","timestamp":1783549098739,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Clayco foundation","award":["900279HY1940"],"award-info":[{"award-number":["900279HY1940"]}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.drudis.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:40:46Z","timestamp":1579693246000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Current status and future prospects of pathophysiology-based neuroprotective drugs for the treatment of vascular dementia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-4486","authenticated-orcid":false,"given":"Kusum","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2117-2613","authenticated-orcid":false,"given":"Chichun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-7040","authenticated-orcid":false,"given":"Rashmi","family":"Kamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Bettermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.01.003_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000455127","article-title":"Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia","volume":"17","author":"Anor","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0010","first-page":"65","article-title":"The borderland between normal aging and dementia","volume":"29","author":"Lo","year":"2017","journal-title":"Ci Ji Yi Xue Za Zhi"},{"key":"10.1016\/j.drudis.2020.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1042\/CS20160607","article-title":"Clinical presentations and epidemiology of vascular dementia","volume":"131","author":"Smith","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.neurol.2017.06.009","article-title":"Vascular cognitive impairment: advances and trends","volume":"173","author":"Barbay","year":"2017","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JAD-170160","article-title":"Framingham Risk Score and the risk of progression from mild cognitive impairment to dementia","volume":"59","author":"Viticchi","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fnagi.2017.00333","article-title":"Systemic and disease-specific risk factors in vascular dementia: diagnosis and prevention","volume":"9","author":"Jaul","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0035","first-page":"69","article-title":"Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis","volume":"7","author":"Santos","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.drudis.2020.01.003_bib0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCRESAHA.116.308426","article-title":"Vascular cognitive impairment","volume":"120","author":"Dichgans","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2020.01.003_bib0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40263-017-0459-3","article-title":"Pharmacotherapy for vascular cognitive impairment","volume":"31","author":"Farooq","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2020.01.003_bib0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1042\/CS20160724","article-title":"Mechanisms of vascular disease in dementia: what does industry want to know?","volume":"131","author":"Wren","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0055","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuropharm.2017.12.030","article-title":"The pathology and pathophysiology of vascular dementia","volume":"134","author":"Kalaria","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2020.01.003_bib0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/CS20171620","article-title":"Small vessels, dementia and chronic diseases \u2013 molecular mechanisms and pathophysiology","volume":"132","author":"Horsburgh","year":"2018","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0065","first-page":"517","article-title":"Neurocognitive disorders other than Alzheimer disease: vascular dementia","volume":"70","author":"Yoshida","year":"2018","journal-title":"Brain Nerve"},{"key":"10.1016\/j.drudis.2020.01.003_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178127","article-title":"Oxidative stress affects processing of amyloid precursor protein in vascular endothelial cells","volume":"12","author":"Muche","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.01.003_bib0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2020.01.003_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2017.96","article-title":"A clinicopathological approach to the diagnosis of dementia","volume":"13","author":"Elahi","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fneur.2017.00233","article-title":"Anti-inflammatory and neuroprotective effects of Co-UltraPEALut in a mouse model of vascular dementia","volume":"8","author":"Siracusa","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnagi.2017.00047","article-title":"White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia","volume":"9","author":"Liu","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000239235","article-title":"Choline acetyltransferase activity in vascular dementia and stroke","volume":"28","author":"Sharp","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.drudis.2020.01.003_bib0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-171166","article-title":"Amyloid-mediated cholinergic dysfunction in motor impairment related to Alzheimer\u2019s disease","volume":"64","author":"Schirinzi","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000476032","article-title":"Cerebrovascular lesions in mixed neurodegenerative dementia: a neuropathological and magnetic resonance study","volume":"78","author":"De Reuck","year":"2017","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brs.2015.09.013","article-title":"Cholinergic circuitry functioning in patients with vascular cognitive impairment\u2014no dementia","volume":"9","author":"Bella","year":"2016","journal-title":"Brain Stimul."},{"key":"10.1016\/j.drudis.2020.01.003_bib0115","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamapsychiatry.2013.4506","article-title":"Synergistic effects of ischemia and beta-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment","volume":"71","author":"Lee","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drudis.2020.01.003_bib0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14737159.2014.922880","article-title":"Interpretation of NOTCH3 mutations in the diagnosis of CADASIL","volume":"14","author":"Rutten","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.drudis.2020.01.003_bib0125","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00415-018-8844-5","article-title":"A novel frameshift variant in the CADASIL gene NOTCH3: pathogenic or not?","volume":"265","author":"Schubert","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0130","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-associated virus-based gene therapy for CNS diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2020.01.003_bib0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ana.24782","article-title":"Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy","volume":"80","author":"Verdura","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clineuro.2017.02.015","article-title":"Hereditary cerebral small vessel disease and stroke","volume":"155","author":"Sondergaard","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.drudis.2020.01.003_bib0145","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2174\/187152711794653832","article-title":"Pharmacotherapy and prevention of vascular dementia","volume":"10","author":"Moretti","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.drudis.2020.01.003_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.drudis.2020.01.003_bib0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jnc.14132","article-title":"Dementia risk and prevention by targeting modifiable vascular risk factors","volume":"144","author":"Tariq","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2020.01.003_bib0160","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1042\/CS20160382","article-title":"Hypercholesterolaemia and vascular dementia","volume":"131","author":"Appleton","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0165","first-page":"507","article-title":"Acetylcholinesterase inhibitors for treatment of Alzheimer\u2019s disease","volume":"66","author":"Shinagawa","year":"2014","journal-title":"Brain Nerve"},{"key":"10.1016\/j.drudis.2020.01.003_bib0170","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.drudis.2020.01.003_bib0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0180","article-title":"Inflammatory markers and imaging patterns of advanced brain aging in the general population","author":"Janowitz","year":"2019","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.drudis.2020.01.003_bib0185","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3233\/JAD-2010-090667","article-title":"Neuroinflammation in Alzheimer\u2019s disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?","volume":"21","author":"Trepanier","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2019.01.007","article-title":"N-Palmitoylethanolamine-oxazoline (PEA-OXA): a new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion","volume":"125","author":"Impellizzeri","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaneurol.2016.5778","article-title":"Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer\u2019s Disease by Vitamin E and Selenium Trial (PREADViSE)","volume":"74","author":"Kryscio","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0200","article-title":"Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life","volume":"12","author":"Rutjes","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2020.01.003_bib0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: time, space and \u2018wingmen\u2019","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013949","article-title":"Screening for familial APP mutations in sporadic cerebral amyloid angiopathy","volume":"5","author":"Biffi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.01.003_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5115\/acb.2016.49.1.1","article-title":"The association between PGC-1\u03b1 and Alzheimer's disease","volume":"49","author":"Sweeney","year":"2016","journal-title":"Anat Cell Biol."},{"issue":"Suppl","key":"10.1016\/j.drudis.2020.01.003_bib0220","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nn938","article-title":"Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches","volume":"5","author":"Thoenen","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0225","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1126\/science.aan8821","article-title":"Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model","volume":"361","author":"Choi","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drudis.2020.01.003_bib0230","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer\u2019s disease\u2013with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.drudis.2020.01.003_bib0235","doi-asserted-by":"crossref","first-page":"12292","DOI":"10.1073\/pnas.1606171113","article-title":"PPARgamma-coactivator-1alpha gene transfer reduces neuronal loss and amyloid-beta generation by reducing beta-secretase in an Alzheimer\u2019s disease model","volume":"113","author":"Katsouri","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2020.01.003_bib0240","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with alzheimer disease: A randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0245","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.neurobiolaging.2013.04.026","article-title":"Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase","volume":"34","author":"Park","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2020.01.003_bib0250","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.taap.2016.11.008","article-title":"A silk peptide fraction restores cognitive function in AF64A-induced Alzheimer disease model rats by increasing expression of choline acetyltransferase gene","volume":"314","author":"Cha","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2020.01.003_bib0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuroscience.2015.01.073","article-title":"Transplantation of NSC-derived cholinergic neuron-like cells improves cognitive function in APP\/PS1 transgenic mice","volume":"291","author":"Gu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2020.01.003_bib0260","first-page":"95","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: A phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.drudis.2020.01.003_bib0265","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.neuron.2016.08.004","article-title":"In vivo reprogramming for CNS repair: regenerating neurons from endogenous glial cells","volume":"91","author":"Li","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2020.01.003_bib0270","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3233\/JAD-160514","article-title":"An oral abeta vaccine using a recombinant adeno-associated virus vector in aged monkeys: reduction in plaque amyloid and increase in abeta oligomers","volume":"54","author":"Hara","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0275","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awz026","article-title":"Functional connectivity associated with tau levels in ageing, Alzheimer\u2019s, and small vessel disease","volume":"142","author":"Franzmeier","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2020.01.003_bib0280","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"issue":"1 Suppl","key":"10.1016\/j.drudis.2020.01.003_bib0285","first-page":"S40","article-title":"Citicoline in vascular cognitive impairment and vascular dementia after stroke","volume":"42","author":"Alvarez-Sabin","year":"2011","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.drudis.2020.01.003_bib0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000346602","article-title":"Long-term treatment with citicoline may improve poststroke vascular cognitive impairment","volume":"35","author":"Alvarez-Sab\u00edn","year":"2013","journal-title":"Cerebrovasc Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0295","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2147\/CIA.S87886","article-title":"The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives","volume":"10","author":"Gareri","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.drudis.2020.01.003_bib0300","doi-asserted-by":"crossref","first-page":"7293626","DOI":"10.1155\/2016\/7293626","article-title":"Herbal medicine for the treatment of vascular dementia: an overview of scientific evidence","author":"Chang","year":"2016","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"10.1016\/j.drudis.2020.01.003_bib0305","first-page":"1","article-title":"Treatment effects of Ginkgo biloba extract EGb 761(R) on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials","author":"Savaskan","year":"2017","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.drudis.2020.01.003_bib0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-015-0014-7","article-title":"Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia","volume":"1","author":"Hashiguchi","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"issue":"5","key":"10.1016\/j.drudis.2020.01.003_bib0315","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40266-019-00648-x","article-title":"Ginkgo biloba extract (EGB761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer\u2019s disease: a network meta-analysis","volume":"36","author":"Thancharoen","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.drudis.2020.01.003_bib0320","article-title":"Traditional Chinese herbal medicine for vascular dementia","volume":"12","author":"Chan","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2020.01.003_bib0325","doi-asserted-by":"crossref","first-page":"6083629","DOI":"10.1155\/2017\/6083629","article-title":"A systematic review of intervention studies examining nutritional and herbal therapies for mild cognitive impairment and dementia using neuroimaging methods: study characteristics and intervention efficacy","author":"Steiner","year":"2017","journal-title":"Evid. Based Complement Alternat. Med."},{"issue":"5","key":"10.1016\/j.drudis.2020.01.003_bib0330","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu115","article-title":"Combination therapy with cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"18","author":"Matsunaga","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.drudis.2020.01.003_bib0335","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2019.01.020","article-title":"Multi-faceted therapeutic strategy for treatment of Alzheimer\u2019s disease by concurrent administration of etodolac and alpha-tocopherol","volume":"125","author":"Elfakhri","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2020.01.003_bib0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2019.03.003","article-title":"A combination of indomethacin and atorvastatin ameliorates cognitive and pathological deterioration in PrP-hAbetaPPswe\/PS1(DeltaE9) transgenic mice","volume":"330","author":"Wang","year":"2019","journal-title":"J. Neuroimmunol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620300295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620300295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:44:46Z","timestamp":1761223486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620300295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1359644620300295"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.01.003","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and future prospects of pathophysiology-based neuroprotective drugs for the treatment of vascular dementia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}